GIM 407
Alternative Names: GIM-407Latest Information Update: 30 Sep 2024
At a glance
- Originator Georgiamune
- Class Small molecules
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
Most Recent Events
- 02 Sep 2024 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Australia (PO) (NCT06536101)
- 02 Aug 2024 Georgiamune plans a phase I trial (In volunteers) in Australia (PO) (NCT06536101)
- 22 Aug 2023 Preclinical trials in Autoimmune disorders in USA (unspecified route) before August 2023 (Georgiamune pipeline, August 2023)